Deciphering the Galectin-1–FIP200 Axis in NAFLD: Mechanistic Insights into Autophagy Suppression

Study Background and Research Question

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder worldwide, presenting a wide spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and ultimately hepatocellular carcinoma. While impaired hepatic autophagy is known to contribute to NAFLD progression, the upstream regulatory factors that suppress autophagic flux under metabolic stress remain incompletely defined. Galectins, particularly galectin-1 (Gal-1), have been implicated in metabolic and inflammatory liver disorders, but their precise mechanistic roles in NAFLD are not well elucidated. The reference study (International Immunopharmacology 185 (2026) 116984) directly addresses this gap by investigating how Gal-1 modulates hepatic autophagy and impacts metabolic dysfunction in NAFLD.

Key Innovation from the Reference Study

The central innovation of the study lies in uncovering a direct molecular mechanism by which Gal-1 impairs hepatic autophagy. The authors demonstrate that Gal-1 interacts with FIP200, a core autophagy scaffold protein, thereby disrupting the assembly of the ULK1 complex and blocking autophagic flux. This Gal-1–FIP200 axis was shown to drive hepatic steatosis and insulin resistance, independent of dietary or environmental triggers, providing a new mechanistic node for the regulation of autophagy in metabolic liver disease. The identification of specific Gal-1 residues (TYR120/PHE134) mediating the interaction with the FIP200 claw domain, with a binding affinity of Kd = 113.1 μM, further refines the therapeutic potential of targeting this interface.

Methods and Experimental Design Insights

The study utilized a combination of in vivo and in vitro models to delineate the effects of Gal-1 on hepatic metabolism and autophagy. Overexpression of Gal-1 in mice recapitulated key features of NAFLD, including steatosis, dyslipidemia, and insulin resistance, even in the absence of dietary challenge. Proteomic and biochemical assays assessed autophagic flux (p62 accumulation, LC3-II conversion), with knock-in and point-mutant models interrogating the Gal-1–FIP200 interaction specificity. Structural mapping and binding assays pinpointed the interaction interface and quantified binding affinity. Cellular models with targeted mutations disrupting Gal-1 binding to FIP200 were used to confirm the functional necessity of this interaction for autophagy suppression and insulin resistance induction.

Protocol Parameters

• Gal-1 overexpression: Achieved via gene delivery in murine hepatocytes; overexpression confirmed at both mRNA and protein levels before phenotype assessment.
• Assessment of autophagic flux: Monitored by immunoblotting for p62 and LC3-II; protease protection assays used to distinguish autophagosome maturation from impaired degradation.
• Gal-1–FIP200 binding analysis: Structural mapping performed by mutagenesis of Gal-1 (TYR120/PHE134) and FIP200 claw domain, followed by co-immunoprecipitation and Kd measurement.
• Insulin resistance evaluation: Conducted using glucose and insulin tolerance tests in vivo, and quantification of Akt phosphorylation in hepatocyte cultures.

Core Findings and Why They Matter

The reference paper demonstrates that hepatic Gal-1 is markedly upregulated in NAFLD and is sufficient to induce pathological lipid accumulation, dyslipidemia, and insulin resistance. Crucially, Gal-1 blocks autophagic flux by binding FIP200 and preventing ULK complex formation, leading to p62 accumulation and impaired lipid clearance. Mutating the Gal-1–FIP200 interaction interface abolishes these effects, indicating that the interaction is both necessary and sufficient for Gal-1-mediated autophagy suppression. This work delineates the Gal-1–FIP200 axis as a distinct regulatory node in NAFLD pathogenesis, which may be leveraged for therapeutic development targeting hepatic autophagy pathways (reference study).

Comparison with Existing Internal Articles

Previous internal reviews have highlighted the significance of ASK1 signaling in hepatic fibrosis and metabolic dysfunction. For example, "Selonsertib (GS-4997): ASK1 Inhibition in Fibrosis & Steatosis Research" discusses the use of ASK1 inhibitors to dissect oxidative stress and inflammatory cascades relevant to NAFLD. However, the present study extends these insights by uncovering a parallel but distinct mechanism—autophagy suppression via Gal-1–FIP200—independent of the classical ASK1 pathway. The internal article "Galectin-1 Disrupts Hepatic Autophagy via FIP200 in NAFLD Progression" summarizes this new regulatory axis, emphasizing its potential as a druggable target. While ASK1 inhibition (e.g., with selonsertib) targets oxidative stress and inflammation, the Gal-1–FIP200 mechanism represents a novel autophagy-centric intervention point within NAFLD research frameworks.

Limitations and Transferability

Although the study provides compelling evidence for the role of Gal-1 in hepatic autophagy suppression, several limitations merit consideration. The primary models used involve murine overexpression systems, which may not fully capture the complexity of human NAFLD etiology. Additionally, the direct translational relevance of the Gal-1–FIP200 interaction for human disease progression and drug targeting requires further validation in clinical samples and diverse genetic backgrounds. Finally, while the study distinguishes this mechanism from established inflammatory and oxidative stress pathways, cross-talk between autophagy regulation and other metabolic signaling axes (such as ASK1) warrants further exploration.

Why this cross-domain matters, maturity, and limitations

The Gal-1–FIP200 axis represents a mechanistically distinct but complementary target alongside established pathways such as ASK1-mediated oxidative stress signaling. Integrating knowledge from both domains could offer multi-pronged strategies for metabolic liver disease intervention, but the maturity of Gal-1–FIP200 targeting remains at the preclinical discovery stage. Rigorous translational and pharmacological studies are needed before clinical application.

Research Support Resources

Researchers aiming to dissect the interplay between autophagy, inflammation, and oxidative stress in NAFLD can employ selective pathway inhibitors to model and manipulate disease mechanisms. Selonsertib (GS-4997) (SKU B7812) from APExBIO is a highly selective ASK1 inhibitor that enables the study of oxidative stress and inflammation signaling in hepatic and renal disease models. While the present study focuses on the Gal-1–FIP200 axis, integrating selonsertib into experimental workflows may help clarify the relationship between ASK1 inhibition and autophagy regulation in NAFLD and related metabolic diseases. For additional protocols and troubleshooting tips, see internal resources on ASK1 inhibition in fibrosis and steatosis research.